A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Clinical trial NCT06670196 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06670196
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-27
- Primary completion
- 2027-05-01
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.